Mesoblast MEOBF
NASDAQ MEOBF
$1.90 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Mesoblast (MEOBF) Non-Current Deffered Revenue (2015 - 2026)

Mesoblast's (MEOBF) quarterly Non-Current Deffered Revenue came in at $2.5 million in Q2 2026, little changed year-over-year from $2.5 million in Q2 2025, and little changed quarter-over-quarter from $2.5 million in Q4 2025.

Analysis

Mesoblast (MEOBF) Non-Current Deffered Revenue (2015 - 2026) Analysis & Trends

Mesoblast has disclosed Non-Current Deffered Revenue across 11 years of filings, most recently posting $2.5 million for Q2 2026.

  • In Q2 2026, Non-Current Deffered Revenue changed 0.0% year-over-year to $2.5 million; the TTM figure through Jun 2026 stood at $2.5 million (changed 0.0% YoY), while the FY2026 annual figure was $2.5 million, changed 0.0% from the prior year.
  • Non-Current Deffered Revenue came in at $2.5 million for Q2 2026 at Mesoblast, roughly flat from $2.5 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $2.5 million in Q1 2022 to a low of $2.5 million in Q1 2022.
  • Average Non-Current Deffered Revenue over 5 years is $2.5 million, with a median of $2.5 million recorded in 2022.
  • The largest YoY upside for Non-Current Deffered Revenue was 0.0% in 2022 against a maximum downside of 0.0% in 2022.
  • Over 5 years, Non-Current Deffered Revenue stood at $2.5 million in 2022, then changed by 0.0% to $2.5 million in 2023, then changed by 0.0% to $2.5 million in 2024, then changed by 0.0% to $2.5 million in 2025, then changed by 0.0% to $2.5 million in 2026.
  • Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $2.5 million in Q2 2026, $2.5 million in Q4 2025, and $2.5 million in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Krystal Biotech 10.27 Bn 9.43 Bn 112.79 Mn -
2 CRISPR Therapeutics AG 5.17 Bn 5.17 Bn - -
3 Iovance Biotherapeutics 3.79 Bn 3.49 Bn 55.72 Mn -
4 Legend Biotech 3.68 Bn 2.71 Bn 251.50 Mn -
5 uniQure 3.05 Bn 3.05 Bn 5.49 Mn -
6 Beam Therapeutics 2.65 Bn 2.65 Bn - -
7 Precigen 2.44 Bn 2.44 Bn 52.17 Mn -
8 Sarepta Therapeutics 2.33 Bn 1.53 Bn 251.87 Mn 110.13 Mn
9 Vericel 1.99 Bn 1.83 Bn 56.40 Mn -
10 Mesoblast 246.02 Mn 143.11 Mn - 2.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.50 Mn
Dec 31, 2025 2.50 Mn
Jun 30, 2025 2.50 Mn
Dec 31, 2024 2.50 Mn
Jun 30, 2024 2.50 Mn
Dec 31, 2023 2.50 Mn
Jun 30, 2023 2.50 Mn
Mar 31, 2023 2.50 Mn
Dec 31, 2022 2.50 Mn
Sep 30, 2022 2.50 Mn
Jun 30, 2022 2.50 Mn
Mar 31, 2022 2.50 Mn
Dec 31, 2021 2.50 Mn
Sep 30, 2021 2.50 Mn
Jun 30, 2021 2.50 Mn
Mar 31, 2021 2.50 Mn
Dec 31, 2020 2.50 Mn
Sep 30, 2020 2.50 Mn
Jun 30, 2020 2.50 Mn
Mar 31, 2020 2.50 Mn